Pharmaxis Ltd. (PXS.AX)

ASX - ASX Delayed Price. Currency in AUD
0.290.00 (0.00%)
At close: 1:59 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.29
Bid0.29 x
Ask0.30 x
Day's Range0.29 - 0.30
52wk Range0.20 - 0.41
1y Target EstN/A
Market Cap93.62M
P/E Ratio (ttm)5.78
Avg Vol (3m)324,308
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Pharmaxis Ltd. :PXS-AU: Earnings Analysis: Q2, 2016 By the Numbers
    Capital Cube4 months ago

    Pharmaxis Ltd. :PXS-AU: Earnings Analysis: Q2, 2016 By the Numbers

    Click here to see latest analysisPharmaxis Ltd. reports financial results for the quarter ended December 31, 2015.HighlightsGross margins narrowed from 4.57% to -126.60% compared to the same period last year, operating (EBITDA) margins now -465.67% from -465.84%.Earnings growth from operating margin improvements as well as one-time items.The table below shows the preliminary results and recent […] (Read more...) The post Pharmaxis Ltd. :PXS-AU: Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.

  • PR Newswire11 months ago

    Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A

    SYDNEY, Sept. 21, 2015 /PRNewswire/ -- Pharmaceutical company Pharmaxis (PXS.AX) today announced positive results for all primary and secondary endpoints from the phase 1 clinical trial of PXS-4728A, a drug that was recently acquired by Boehringer Ingelheim to develop as a treatment for cardiometabolic diseases such as Non-Alcoholic Steatohepatitis (NASH). PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein (SSAO/VAP-1 encoded by the AOC3 gene) which reduces inflammation and oxidative stress. The data confirmed the high oral bioavailability of PXS-4728A and most importantly, showed these low doses are efficacious in inhibiting the enzyme and cause a long lasting inhibition suggesting PXS-4728A can be dosed once a day.

  • Motley Fool2 years ago

    The big reason why Pharmaxis Ltd shares slumped today

    Biotech could be running out of options